Cryptocurrency News
Global Pharma Giant Develops DLT-Based Care Network for Diabetes Patients
- Solve.Care and giant pharmaceutical firm, Boehringer Ingelheim to work together to help diabetes patients.
- The companies will launch a new software system that is based on distributed ledger technology (DLT).
Cointelegraph shared a press release on June 6 stating the team-up of two companies in the health care industry – Boehringer Ingelheim, a leading pharmaceutical firm, and Solve.Care, a healthcare company which uses blockchain technology.
The team’s aim is to construct a digital asset and blockchain-powered network that can provide reliable data sharing of a great number of diabetes patients.
Diabetes Care Administration Network
This new system is named Diabetes Care Administration Network as founded by Solve.Care. The network’s aim is to provide diabetes patients with assistance and care through various information related to risks, symptoms, and prevention of diabetes.
In order to support patients with diabetes, the network shall implement a care coordination device called Care.Wallets which is created by Solve.Care.
Thousands of Diabetes Patients Expected to Benefit from New Software
There will be more than 25,000 diabetics who shall benefit from the said system from the get-go. These patients shall come from Arizona Care Network (ACN), a major American accountable care firm. And Before the year ends 2019, the care network is expected to go live.
Currently, another partnership was established blockchain-enabled pharmaceutical consortium MediLedger and global retail giant Walmart followed by four other American firms including one of the pharmaceutical brands, Pfizer.
In a statement released by Cointelegraph previously, the report stated that Tron Foundation, a major cryptocurrency project partnered with the Association of Amyotrophic Lateral Sclerosis aka ALS. The purpose of this partnership is basically to establish a charity campaign that will enable people to gather ALS awareness and at the same time raise funds for research on the treatment of the disease.